



Supplementary




Supplementary Fig. 1 Structure of FGF21 C-terminal tail in complex with β -klotho (PDB:5VAQ). KLB (blue) is shown as surface and FGF21 C-tail (yellow) is shown as backbone stick representations. S167 and R175 (green) are labeled and shown as ball & stick representation.


a



b




c




Supplementary Fig. 2 Characterization of FGF21 fusion proteins. a. SDS PAGE of Fc-FGF21 purified by protein A column affinity chromatography. b. SDS PAGE of GLP-1-Fc-FGF21 purified by protein A column affinity chromatography. c. The mass spectrometry

detection diagrams of Fc-FGF21 S1 and GLP-1-Fc-FGF21 D1 fusion proteins. The mass spectra are assigned to the corresponding m/z values.




Supplementary Fig. 3 Kinetic analysis of the interaction between FGF21 mutants and β -Klotho. Data were processed and curve fit using a 1:1 binding model.




Supplementary Fig. 4 The receptor expression of HEK293/GLP-1R, HEK293/ β -Klotho or HEK293/GLP-1R- β -Klotho were assessed by flow cytometry analysis. (a) Data shown are representative histograms from flow cytometry showing expression for GLP-1R in HEK293/GLP-1R cell line. (b) and for GLP-1R in HEK293/ GLP-1R- β -Klotho cell line. (c) and for β -Klotho in HEK293/ β -Klotho cell line. (d) and for β -Klotho in HEK293/ GLP-1R- β -Klotho cell line. Isotype control antibody at the same concentration was used as a negative control.

(a)



(b)



Supplementary Fig. 5 PK profiles of D1 in mice and rats. (A) Mean plasma concentration-time profiles in mice following single SC administrations at 1 mg/kg. (B) Mean plasma concentration-time profiles in rats following single SC administrations at 0.5 mg/kg. Values presented are Mean \pm SD with $n = 5$ for mice and rats.

Species	Dose (mg/kg)	Route	AUC _{last} ($\mu\text{g}\cdot\text{h}/\text{mL}$)	C _{max} (ng/mL)	T _{max} (h)	MRT (h)	t _{1/2} (h)	CL/F (mL/h/kg)	Vz/F (mL/kg)
Mouse	1	SC	82.2 \pm 16	2010 \pm 190	7.8 \pm 3.8	35.5 \pm 2.7	30.3 \pm 1.6	12.3 \pm 2.6	541 \pm 140
Rat	0.5	SC	24.9 \pm 4.5	659 \pm 98	12.0 \pm 0.0	31.6 \pm 3.3	25.9 \pm 2.5	20.2 \pm 3.6	746 \pm 94

Supplementary Table 4 Pharmacokinetic parameters in C57BL6 mice and Sprague-Dawley rats. Plasma concentrations of D1 were determined with a sandwich ELISA recognizing the N-terminus of the GLP-1 portion and the Fc portion. AUC_{last}, area under the curve from the time of dosing to the last measurable concentration; C_{max}, maximum observed concentration; T_{max}, time to C_{max}; MRT, mean residence time; t_{1/2}, terminal half-life; CL/F, total body clearance for extravascular administration; Vz/F, volume of distribution as a function of bioavailability. All values are expressed as (Means \pm SD) with $n = 5$ for mice and rats.

GLP-1	HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG
FGF21	HPIPDSSPLLQFGGQVRQRYLYTDDAQQTEAHLEIREDDGTVGGAADQSPESLLQLKA LKPGVIQILGVKTSRFLCQRPDGALYGS LHFDP EACSF RERLLEDGYNVYQSEAHGLP LHLPGNKSPHRDPAPRGPAPRFLPLPGLPPALPEPPGILAPQPPDVGSSDPLHMVGASQ GLSPSYAS

Supplementary Table 5 The sequences for GLP-1 and FGF21 in GLP-1-Fc-FGF21 D1.